Comparing the Roles of Omalizumab and Ultraviolet Therapy in Treating Severe Pediatric Atopic Dermatitis

To the Editor In their study, Chan et al report the effectiveness of omalizumab in treating severe pediatric atopic dermatitis, with significant clinical benefit. While these encouraging results suggest that omalizumab may be a viable treatment option for this patient group, the Editorial on this study succinctly raised the issue of cost-effectiveness because the cost of omalizumab administration could amount to greater than $100  000 per year. Thus, there needs to be a strong rationale for using omalizumab in favor of other treatment options.
Source: JAMA Pediatrics - Category: Pediatrics Source Type: research